Author/Creator: Innes, A - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Innes, A

1. B.06 Whole exome sequencing in genetic ataxias associated with cerebellar atrophy: the Canadian experience. (5th June 2019)

Authors:: Gauquelin, L; Hartley, T; Tarnopolsky, M; Dyment, DA; Brais, B; Geraghty, MT; Tétreault, M; Ahmed, S; Rojas, S; Majewski, J; Bernier, F; Innes, A; Rouleau, G; Suchowersky, O; Boycott, KM; Yoon, G
Journal:: Canadian journal of neurological sciences
Issue:: Volume 46(2019)Supplement 1
Page Start:: S11
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. B.06 Whole exome sequencing in genetic ataxias associated with cerebellar atrophy: the Canadian experience. (June 2019)

Authors:: Gauquelin, L; Hartley, T; Tarnopolsky, M; Dyment, DA; Brais, B; Geraghty, MT; Tétreault, M; Ahmed, S; Rojas, S; Majewski, J; Bernier, F; Innes, A; Rouleau, G; Suchowersky, O; Boycott, KM; Yoon, G
Journal:: Canadian journal of neurological sciences
Issue:: Volume 46(2019)Supplement 1
Page Start:: S11
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Issue 10 (10th September 2004)

Authors:: Sandborn, W J; Feagan, B G; Radford-Smith, G; Kovacs, A; Enns, R; Innes, A; Patel, J
Journal:: Gut
Issue:: Volume 53:Issue 10(2004)
Page Start:: 1485
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Complement activation by cellulosic dialysis membranes. Issue 2 (February 1994)

Authors:: Innes, A; Farrell, A M; Burden, R P; Morgan, A G; Powell, R J
Journal:: Journal of clinical pathology
Issue:: Volume 47:Issue 2(1994)
Page Start:: 155
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Issue 6 (17th November 2008)

Authors:: Fleischmann, R; Vencovsky, J; van Vollenhoven, R F; Borenstein, D; Box, J; Coteur, G; Goel, N; Brezinschek, H-P; Innes, A; Strand, V
Journal:: Annals of the rheumatic diseases
Issue:: Volume 68:Issue 6(2009)
Page Start:: 805
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. P96 Repeat Administration of GL67A/pGM169 is Feasible, Safe, and Produces Endogenous Levels of CFTR Expression After 12 Doses. (19th November 2012)

Authors:: Alton, EWFW; Boyd, AC; Cheng, SH; Davies, J; Davies, LA; Dayan, A; Gill, DR; Griesenbach, U; Higgins, T; Hyde, SC; Innes, A; McLachlan, G; Porteous, D; Pringle, IA; Scheule, RK; Sumner-Jones, SG
Journal:: Thorax
Issue:: Volume 67(2012)Supplement 2
Page Start:: A105
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗